70results about How to "Sustained effect" patented technology

Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques disclosed.

The present invention provides a microneedle device having a coating, which is effective even with a low molecular weight active compound and can sustain the effect of the drug for a long period of time, and a transdermal drug administration apparatus with microneedles. The microneedle device (5) has, on a microneedle substrate (8), a plurality of microneedles (6) that can pierce the skin, wherein the surface of the microneedles (6) and/or the microneedle substrate (8) is partly or entirely coated in fixed state with a coating carrier containing polyvinyl alcohol. The polyvinyl alcohol preferably has a hydrolysis degree of 94.5 mol % or more. Furthermore, the coating carrier can contain a drug.

Provided are: a non-aqueous electrolyte solution for a secondary battery that exhibits both excellent low-temperature discharge characteristics and excellent cycle characteristics on a long-term basis; and a secondary battery.

A non-aqueous electrolyte solution for a non-aqueous electrolyte secondary battery that has a positive electrode and a negative electrode capable of the absorbing and releasing of a metal ion, and a separator,

• • the non-aqueous electrolyte solution comprising, in addition to an electrolyte and a non-aqueous solvent, 0.01 mass % or more to less than 3 mass % of a compound having one or more partial structure represented by the following general formula (1) and two or more isocyanate groups in the molecule:

(In the general formula (1), R represents hydrogen or a C₁-C₁₂ organic group that may contain an isocyanate group and is constituted of atoms selected from the group consisting of hydrogen atom, carbon atom, nitrogen atom, oxygen atom, sulfur atom, phosphorus atom, and halogen atom).

There is provided an antibacterial fiber, an antibacterial twisted yarn and an antibacterial cloth which exhibits high durability to post-processing with water, detergent, staining or the like at a small added amount. In an antibacterial fiber200, an antibacterial property imparting glass composition10 is fixed in a form of, for example, a particle on the surface of a fiber substrate16 and/or dispersed and complexed in the fiber substrate16. An antibacterial property imparting glass composition10 comprises 0.1 to 5.0% by weight of Ag2O in a composition containing 45-67 mol % of P2O5, 5 to 20 mol % of Al2O3, 1 to 40 mol % of 1 or 2 or more selected from MgO, CaO and ZnO, and 20 mol % or less of B2O3. An antibacterial fiber200 containing such the antibacterial property imparting glass composition10 at a ratio of, for example, 0.1 to 5.0% by weight shows high water resistance, acid resistance, alkali resistance and detergent resistance in antibacterial property.

Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II

or a salt thereof, in which R¹, R², R³, R¹⁰⁰, R²⁰⁰, R³⁰⁰, A, A¹, BG, Q and Q¹ are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.

Disclosed are controlled release dosage forms of pharmaceutical or nutritional agents that are intended for retention in a buccal or sublingual location for administration. The dosage forms are particularly useful for the sustained release administration of drugs that have a limited window of absorption in the gastrointestinal tract and that are minimally, if at all, absorbed mucosally.

A propeller shaft having high wear resistance is provided. The propeller shaft has a spline shaft and a spline sleeve meshing with each other, and a DLC coating is applied to any one of the spline shaft and the spline sleeve. The DLC coating has surface roughness Ra of 0.5 μm or smaller.

Pharmaceutical compositions comprising modafinil. The pharmaceutical compositions can have a release profile which is different than that of traditional pharmaceutical compositions of modafinil.

A percutaneous absorption type ophthalmic preparation comprising muscarinic receptor agonist is prepared, which can promote lacrimal fluid secretion by administration to the skin surface of the eyelid, and which causes fewer side effects such as miosis, thereby to provide a percutaneous absorption type ophthalmic preparation capable of maintaining a therapeutically effective concentration of a muscarinic receptor agonist for promoting lacrimal fluid secretion, which is associated with fewer side effects such as miosis, and a method of promoting lacrimal fluid secretion by administering a percutaneous absorption type ophthalmic preparation containing a muscarinic receptor agonist to the skin surface of the eyelid.

The invention provides an allergen inactivating method by maintaining the allergens under a condition in which any one selected from the group consisting of heat, an alkali, an acid and an enzyme exists.

The present invention provides a bonding apparatus in which solder is conveyed onto a predetermined electrode, and the solder is melted by irradiation of a laser beam and is bonded to the electrode and has an object to prevent the solder from adhering to a solder conveying system of the apparatus. To achieve the above object, in the bonding apparatus, a film having low wettability to the solder and having a predetermined thickness such as a DLC film is coated on a region and a neighborhood of a solder holding and conveying member, which is contacted with the solder.

A modified coffee containing 3 mg or more of a nicotinic acid compound and 10 mg or more of a Maillard reaction product per 10 g of roasted coffee beans. A coffee-like supplement containing at least one nicotinic acid compound, at least one Maillard reaction product, and/or at least one metabolite of the Maillard reaction product.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an antihistamine for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

The invention relates to compositions, methods and uses comprising an epi-inositol compound that provides beneficial effects in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence. In aspects of the invention, the epi-inositol compounds provide beneficial effects in the treatment of Alzheimer's disease, dementia, and mild cognitive impairment.

A long-acting improver of muscular fatigue characterized by comprising 4 kinds of amino acids made up of leucine, isoleucine, valine and glutamine, and a whey protein component (whey protein and/or decomposition product of whey protein). At least one of a whey protein isolate (WPI), a whey protein concentrate (WPC), β-lactoglobulin, and α-lactalbumin is used as the whey protein. Novel food or drink, and pharmaceuticals which exhibit sustained recovery effects on muscular fatigue are provided.

The present invention provides an antibacterial glass composition exhibiting high antibacterial performance with sufficiently sustaining antibacterial performance by adding a small amount of the antibacterial component, and an antibacterial polymer composition using the antibacterial glass composition. The present invention provides an antibacterial glass composition containing 0.1 to 5.0% by weight of Ag2O in a glass composition containing 30 to 60 mol % of P2O5, 1 to 15 mol % of one or more compounds selected from the group consisting of K2O, Na2O and Li2O, 35 to 55 mol % of one or more compounds selected from the group consisting of MgO, CaO and ZnO, and 0.01 to 3 mol % of one or more compounds selected from the group consisting of La2O3 and Y2O3.

The invention discloses a novel low-toxicity tripterygium polyglycoside. The novel low-toxicity tripterygium polyglycoside is obtained via chemical processing and adding of triptolide. The invention also discloses applications of the novel low-toxicity tripterygium polyglycoside in the field of medicine. The novel low-toxicity tripterygium polyglycoside is capable of relieving nephrotic syndromes such as kidney pathological injury and proteinuria, improving body inflammation level, possesses obvious curative effect on nephrotic syndromes, is low in toxicity, and effect lasts long.

An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I):

wherein R¹ is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa):

wherein R⁴ is lower alkyl, R³ is lower alkylene, and m is an integer of 1 to 6;

• • R² is lower alkyl optionally substituted with phenyl; and
  • R³ is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

The invention features compositions and methods that are useful for preventing or treating a cardiac disease or for promoting cardiac health following a myocardial infarction. The invention further features compositions and methods for promoting angiogenesis, cell proliferation, and/or decreasing apoptosis in muscle tissue, such as cardiac tissue. The invention provides for the expression of human growth hormone in cardiac muscle following a myocardial infarction.